Eurocine Vaccines has received a Notice of Decision to Grant from the Korean Intellectual Property Office, covering inventions relevant for the newly added vaccine candidate against HSV-2, Herpes Simplex Virus Type 2. Adding South Korea to the territories with granted patents is well in line with the company´s global patent strategy as it is considered one of the four most important pharmaceutical markets in Asia.
The received Notice of Decision to Grant not only provides strengthened protection for the technology, but it also validates the level of innovation for the innovation. The patent is valid until 2037.
– Patents with a commercially relevant protection constitutes a crucial part of our work, onboarding new candidates. The HSV-2 vaccine candidate is no exception, where patents today are approved or pending for major markets worldwide, says CEO Hans Arwidsson.
Previous News Releases about the HSV-2 vaccine candidate include:
Expansion of portfolio with a therapeutic HSV-2 vaccine candidate
Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Strategic development plan for the newly added therapeutic HSV-2 vaccine candidate
Read more about our portfolio, vaccine candidates and needs they address.
Eurocine Vaccines´ portfolio